CG
NAMS icon

Cutler Group’s NewAmsterdam Pharma NAMS Stock Holding History

Cutler Group’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-500
Closed -$5K – 3129
2023
Q4 		$5K Hold
500
– – ﹤0.01% 2745
2023
Q3 		$4K Hold
500
– – ﹤0.01% 2984
2023
Q2 		$5K Buy
+500
New +$6.63K ﹤0.01% 2632

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Cutler Group's NAMS Position: Q1 2024 in Review

Cutler Group sold out of NewAmsterdam Pharma (NAMS) in Q1 2024, closing a stake of 500 shares — an estimated $5K sold.

Cutler Group first reported a position in NAMS in Q2 2023 and held it in 3 quarters. The position peaked at $5K in Q4 2023. 76 funds tracked by Wall St. Rank hold NAMS as of Q1 2024.

  • Cutler Group reported no remaining NewAmsterdam Pharma position as of Q1 2024 after selling out during the quarter.
  • Cutler Group sold 500 NewAmsterdam Pharma shares in Q1 2024, an estimated $5K.
  • Cutler Group first reported a position in NewAmsterdam Pharma in Q2 2023 and held it in 3 quarters.
  • Cutler Group's NewAmsterdam Pharma position peaked at $5K in Q4 2023.
  • 76 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.